Keywords: bone marrow transplant; peripheral blood stem cell transplant; epidemiology; transplant activity; Europe; coefficient of variation In 1995, a total of 12 101 blood or marrow transplants, performed in Europe by 343 teams from 31 countries, were reported to the European Group for Blood and Marrow Transplantation (EBMT). Of these, 3858 (32%)
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Severe aplastic anemia + Fanconi  180  12  4  4  3  -34  ----237  -237  Thalassemia  143  5  ----1  ----149  -149  SCID  13  1  25  7  --11  ----57  -57  Inborn errors  36  3  12  7  --29  1  ---88  -88  Others  42  6  3  ---10  -3  28  -61  31  92   Total  2368 413  145  131  25  12  749  15  1384 6504 355 3858 8243 12101 HLA-id = identical sibling donor; Non-id = family donor other than HLA-identical sibling; BM = bone marrow; PBPC = peripheral precursor blood cells; Both = bone marrow + peripheral precursor blood cells; Allo = total of allogeneic transplants; Auto = total of autologous transplants.
performed in 1995 in Albania, Andorra, Armenia, Azerbai-37 more teams. 8 The report includes EBMT member teams and all teams except five reporting to the 1994 survey jan, Bosnia-Herzegovina, Bulgaria, Cyprus, Georgia, Iceland, Latvia, Liechtenstein, Lithuania, Macedonia, Malta, (response = 98.5%). The majority of the teams, ie 71%, do both allogeneic Moldovia, Monaco, Romania, San Marino, Ukraine and Vatican.
and autologous transplants, 28% of the teams restrict their activity to autologous, 1% to allogeneic transplants only The relative transplant activity per 10 million inhabitants was calculated for participating countries by computing the ( Table 2) . number of teams and transplants against the number of inhabitants as taken from the Fischer's Weltalmanach 11 (Table 2 ). The same calculations were repeated for the allogeneic, autologous and unrelated transplants separately.
Transplant figures
A total of 12 101 transplants, 3858 allogeneic (32%) and 8243 autologous (68%) were performed in 1995. This repThe coefficient of variation was used, as previously described, to assess consensus for certain indications. 12 The resents a marked increase of 13% compared to 10 666 transplants in 1994 (3502 allogeneic, 6564 autologous) resulting number of transplants per 10 million inhabitants was calculated for each indication and country. The coefficient of from both an increase in new teams and higher numbers of transplants by established teams. The 306 teams participatvariation was determined for those indications with at least 100 transplants among those 14 European countries that ing in both the 1994 8 and 1995 survey showed an increase from 10 666 to 11 336 transplants, as illustrated in Table 4 . also had at least 100 transplants in 1995 (Tables 3a and b) .
Main indications

Results
The main indications for transplants remain lymphomas (39%), leukemias (36%), solid tumors (20%), severe aplasThree hundred and forty-three participating teams from 31 countries reported to the survey. Compared to the 1994 surtic anemia (2%) and congenital disorders (2%). Details are listed in Table 1 source. Table 3 illustrates the main indications for the 306 ranges from Ͻ1 to Ͼ10 per 10 million inhabitants ( Figure 1 ). The number of teams does not correlate with teams which took part in both the 1994 8 and 1995 survey. There is a rise in absolute numbers, but no change in relathe total number of transplants. In general, differences in transplant activity are similar for the total of transplants tive proportions. 
Donor type and source
The very high number of transplants per 10 million For the 3858 allogeneic transplants, donors were an HLAinhabitants in Israel might in part be explained by a high identical sibling (72%) for 2781 recipients, an HLA nonfrequency of transplants for patients who are not residents identical family member (8%) for 276 recipients, a synof this country (personal communication S Slavin). geneic twin (4%) for 37 recipients and an unrelated, matched, volunteer donor (20%) for 764 recipients. ComVariation of transplant frequency by indication pared to 1994 there is an absolute and relative increase in
The number of transplants per 10 million inhabitants for unrelated transplants from 385 (17%) to 764 (20%). Periphselected indications is illustrated in Tables 3a (leukemias) eral blood continues to replace bone marrow as a transplant and b (myeloproliferative disorders) and c (solid tumors, source (Table 1) . 6504 (79%) of the autologous and 571
severe aplastic anemia and congenital disorders). The coef-(15%) of the allogeneic transplants were peripheral blood ficient of variation between those 14 countries with at least stem cell transplants. 13 100 transplants in 1995 ranges from 39.7 to 201.7% (Tables 3a and b) . It confirms previous findings with a narTransplant frequency per number of inhabitants rowest coefficient of variation for chronic myeloid leukemia (39.7%) in allogeneic and for Hodgkin's disease There are significant differences between the participating countries, as illustrated in Table 2 . The number of teams (44.8%) in autologous transplants. In contrast, a wide coef- ficient of variation for thalassemia (20.8%) and some indications for blood and marrow transplants in Europe. No information is given on outcome. These data are collected cations for solid tumor autografts, such as carcinoma of the breast (92.7%).
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and reported elsewhere. 14 The report clearly underscores the rapid evolution of blood and marrow transplantation from what was an experimental undertaking 25 years ago 15 to an established procedure today. More than 12 000 such Discussion transplants were performed last year in Europe, an estimated number of 30 000 worldwide. This evolution appears The present report, the sixth of a series, gives information on transplant figures, donor sources, donor types and indiunbroken despite increasing economic difficulties. The Neuro = neuroblastoma; Germinal = germinal tumors; Breast = breast carcinoma; SAA + Fan = severe aplastic anemia + Fanconi anemia; SCID + IE = severe combined immune deficiencies and inborn errors. Leukemia  4193  37  2825  67  1368  33  4408  36  2977  68  1431  32  Lymphoma  4339  38  255  6  4084  94  4671  39  272  6  4399  94  SAA  224  2  224  100  0  0  237  2  237  100  0  0  Solid tumors  2225  20  17  1  2208  99  2399  20  17  1  2382  99  Congenital disorders  271  2  271  100  0  0  294  2  294  100  0  0  Others  84  1  56  67  28  33  92  1  61  66  31  34   Total  11336  100  3648  32  7688  68  12101  100  3858  32  8243  68 No. = number of transplants; Allo = allogeneic transplants; Auto = autologous transplants; SAA = severe aplastic anemia.
trend is likely to continue. Recent publications of prospecobserved between European countries, when indications for individual diseases are analyzed in relation to the number tive controlled randomized studies document the value of high-dose therapy and autologous stem cell support. [16] [17] [18] of inhabitants per country. The coefficient of variation has been confirmed as an adequate tool for assessment of conClear data document the potential of healthy allogeneic cells for providing a graft-versus-tumor response 19 and cord sensus on medical indications. This is evident for those diseases with the same relative frequency in most European blood is emerging as a new source of stem cells for those patients with no potential for autologous transplants and no countries. 12 According to available data, this is probably the case for most hematological malignancies in Europe. 23 family donor.
20,21
The current analysis concentrates on differences among It is different for some congenital diseases, such as thalassemia. the participating European countries as regards transplant activity and transplant indications. It confirms previously In summary, collection of transplant activity data, in connection with previous reports and those of sister organizaobserved discrepancies in procedure availability between Western and Eastern Europe which reflect differences in tions, provides a valuable method for the observation of trends and the establishment of consensus or dissension economic status between these countries. 22 It is comforting to note an increasing activity at least in some Eastern Euroamongst treating physicians. These data form the basis for health care planning, procurement of guidelines and pean countries. Further to economic aspects, heterogeneity in medical opinion explains some of the differences recommendations for patient counselling. 
